USPTO To Reexamine Lipitor Patent
In a troubling development for Pfizer Inc., the U.S. Patent and Trademark Office has agreed to reexamine the drug maker's patent on the cholesterol-lowering treatment Lipitor, the world's best-selling drug....To view the full article, register now.
Already a subscriber? Click here to view full article